Advertisement

Advertisement

NCCN 2020 Virtual Congress: Hematologic Malignancies

By Alice Goodman / November 10, 2020 / NCCN 2020 Virtual Congress: Hematologic Malignancies

Chronic Lymphocytic Leukemia: New Treatments Achieve Deeper Remissions

At the National Comprehensive Cancer Network® (NCCN®) 2020 Virtual Congress: Hematologic Malignancies, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, reviewed ...

By Alice Goodman / November 10, 2020 / NCCN 2020 Virtual Congress: Hematologic Malignancies

Do All Patients With Refractory Diffuse Large B-Cell Lymphoma Need CAR T-Cell Therapy?

Chimeric antigen receptor (CAR) T-cell therapy has made great strides in treating patients with relapsed or refractory diffuse large-B cell lymphoma (DLBCL) and refractory mantle cell lymphoma (MCL), ...

Advertisement

Advertisement

Nov

21

Today In Oncology

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

Advertisement

© 2024 HSP News Service, L.L.C.